For example, a phase 1 clinical trial was conducted in which the bisphosphonate zoledronate, a Vγ9Vδ2 T-cell agonist, plus low-dose interleukin-2 (IL-2), were administered to terminal advanced metastatic BC patients. The gene discussed is IL2; the disease is breast cancer.